Case Study | MS / mRNA Vaccine Response
How AcceleTrial identified specialist MS sites with vaccine-naive patient populations for an mRNA vaccine response trial, with documents collected at 50% the standard rate.
Finding 10 sites with access to vaccine-naive MS patients, a specialized sub-population with strict eligibility criteria.
Executing CDAs and Feasibility Questionnaires with clinical sites under an accelerated schedule.
Activating sites efficiently to exceed targeted timelines for a novel mRNA study modality.
Using AcceleTrial, LINEA identified 12 MS sites with specific expertise and vaccine-naive patient access. Documents were collected at 50% the standard rate. Sites were evaluated against trial history, COVID-readiness, debarment status, and clinical experience.
Exceeded sponsor target of 10, providing both the selected pool and reserve sites.
CDAs and FQs collected at half the standard timeline through AcceleTrial automation.
7 LINEA-sourced sites chosen for the mRNA vaccine response study.